GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Abivax ABVX.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

77.70

+0.71%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Abivax

Its shares trade on Euronext Paris under the ticker ABVX.PA. It has been listed since 26 June 2015. In the fiscal year to 31 December 2024, it reported revenue of €10.8m and a net loss of €176.2m. At that date it held total assets of €205.2m and shareholders' equity of €40.6m.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
26 Jun 2015
Employees
27
Website
abivax.com ↗

Leadership

Pay as last reported

  • Dr. Sylvie GregoireChairwoman of the Board
  • Mr. Marc De GaridelChief Executive Officer, since 2023€605,352
  • Mr. Didier BlondelChief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
  • Ms. Ida HatoumChief People Officer, Chief Compliance Officer
  • Mr. Jerome DenisExecutive Vice President - Process Development & Manufacturing, since 2024
  • Ms. Hema KeshavaSenior Vice President - Finance
  • Mr. Patrick MalloySenior Vice President - Investor Relations
  • Ms. Nadege Briancon-erisSenior Vice President, Global Head - Program Management
  • Ms. Jennifer FineSenior Vice President, Global Head - HEOR and RWE
  • Dr. Douglas JacobsteinSenior Vice President, Global Head - Clinical Development
  • Ms. Mary MantockSenior Vice President, Global Head - Regulatory Affairs
  • Mr. Didier ScherrerChief Scientific Officer, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Abivax SA possesses several key strengths that contribute to its success:

Weaknesses

  • Despite its strengths, Abivax SA faces certain weaknesses that need to be addressed:

Opportunities

  • Abivax SA can capitalize on various opportunities within the biotech industry:

Threats

  • Abivax SA should also be mindful of the following threats that could impact its growth:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.